← Back to all trials
Completed
NCT05716932
Focal Laser Single Intravitreal Ranibizumab Retinal Artery Macroaneurysm.
Conditions: Retinal Artery Macroaneurysm
Sex: All
Enrollment: 14
Sponsor: Dar El Oyoun Hospital
Location: Egypt
Summary
Treatment options for Retinal artery Macroaneurysm (RAM) include focal laser photocoagulation, intravitreal anti-Vascular Endothelial Growth Factor (anti-VEGF) injection, combined anti VEGF - laser therapy, YAG hyaloidotomy and pars plana vitrectomy.
Focal laser photocoagulation is applied directly to the macroaneurysm (direct lesional), its surrounding area (indirect perilesional) or a combination of both.
[3-5] Anti-VEGF agents including bevacizumab and ranibizumab reduce leakage from the macroaneurysm.
[3-15] YAG hyaloidotomy is used for fresh premacular hemorrhage.
[16] Pars plana vitrectomy is reserved for RAM complicated by vitreous and/or premacular hemorrhage.
[17]However, there is no consensus about laser and anti VEGF treatments.
Some authors use perilesional laser, while others use direct laser only.
There is also no clear protocol for anti VEGF injections.
Some authors report using focal laser only if multiple anti VEGF injections do not result in marked improvement.
[3-17].
Eligibility Criteria
Inclusion Criteria:We will enroll cases of RAM that had been treated by Direct and perilesional focal laser, followed by a single intravitreal ranibizumab injection a few days later, and had been followed up for at least 6 monthsExclusion Criteria:• RAM treated by a single approach (laser or intravitreal injections),RAM treated by other anti-VEGF injections (not ranibizumab),RAM with a shorter than 6 months of follow-up after combined laser and ranibizumab
Source: ClinicalTrials.gov (NCT05716932). StuddyBuddy aggregates publicly available trial information.
